Related Experiment Video
Updated: Apr 5, 2026

10:20
Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice
Published on: January 16, 2013
26.2K
EETs Elicit Direct Increases in Pulmonary Arterial Pressure in Mice
Sharath Kandhi1, Ghezal Froogh1, Jun Qin2
1Department of Physiology, New York Medical College, Valhalla, New York, New York, USA;
American Journal of Hypertension
|August 26, 2015
Summary
Epoxyeicosatrienoic acids (EETs) directly increase right ventricular systolic pressure (RVSP), potentially contributing to pulmonary hypertension. This study investigated EETs
Area of Science:
- Cardiovascular Physiology
- Pulmonary Circulation
- Vascular Biology
Background:
- The precise role of epoxyeicosatrienoic acids (EETs) in regulating pulmonary circulation remains unclear.
- EETs are known vasoactive lipids, but their specific impact on right ventricular systolic pressure (RVSP) is debated.
Purpose of the Study:
- To investigate the hypothesis that EETs elevate RVSP, possibly through pulmonary vasoconstriction.
- To elucidate the direct effects of EETs on RVSP independent of systemic blood pressure changes.
Main Methods:
- Anesthetized mice were instrumented with catheters for infusing EETs, monitoring blood pressure (BP), and RVSP.
- Four regioisomeric EETs were administered at various doses, and responses were recorded under basal and hypoxic conditions.
- Direct right ventricular injections of 14,15-EET were performed to assess RVSP changes independently of systemic BP.
Main Results:
- All tested EETs induced dose-dependent increases in RVSP with concurrent decreases in BP.
- 11,12-EET demonstrated the most significant increase in RVSP.
- Direct right ventricular administration of 14,15-EET elevated RVSP without affecting systemic BP, confirming a direct pulmonary effect.
- Hypoxia exposure potentiated both basal RVSP and EET-induced increases in RVSP.
Conclusions:
- EETs directly increase RVSP, suggesting a significant role in pulmonary circulation regulation.
- This EET-mediated elevation of RVSP may be a key factor in the pathogenesis of hypoxia-induced pulmonary hypertension (PH).
Keywords:
epoxyeicosatrienoic acidshypertensionhypoxiamean arterial blood pressurepulmonary circulationright ventricular systolic pressure.More Related Videos
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
564
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
564
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
609
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
609

